OncoMatch/Clinical Trials/NCT06607796
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
Is NCT06607796 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Toluenesulfonamide (PTS) Intratumoral for lung cancer.
Treatment: Toluenesulfonamide (PTS) Intratumoral — The aim of this study was to evaluate the efficacy and safety of intratumoral injection of toluenesulfonamide(PTS) in combination with or without first-line chemoimmunization based on standard treatment for stage IV driver gene-negative non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
driver gene negative
Required: ALK wild-type
driver gene negative
Required: ROS1 wild-type
driver gene negative
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemoimmunotherapy — first-line
Lab requirements
Blood counts
normal blood routine, blood biochemistry, coagulation function and electrolytes
Kidney function
normal kidney function
Liver function
normal liver function
Cardiac function
normal heart function
Normal liver, kidney and heart function, normal blood routine, blood biochemistry, coagulation function and electrolytes and other physiological indicators
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify